Adherence to Non-pharmacologic Therapy for Hypertension: Problems and Solutions
نویسندگان
چکیده
منابع مشابه
Adherence to pharmacologic management of hypertension.
Adherence to pharmacologic therapy of hypertension is low (in the range of 50-70%) and has important implications both for blood pressure control and cardiovascular complications. Based on a review of the literature using the levels of evidence grading technique, determinants of adherence to the pharmacologic therapy of hypertension have been assessed. Additionally, interventions to improve com...
متن کاملNon-Pharmacologic Treatments for Fear of Flying
The purpose of the present survey was to review the important Non-pharmacologic treatments for fear of flying up to the present. This study is in the same way as some studies. Accordingly, some Non-pharmacologic treatments for fear of flying were assessed through this systematic review article. The general conclusion from the information provided by the former studies, shows that a growing num...
متن کاملIntensifying therapy for hypertension despite suboptimal adherence.
More intensive management can improve control blood pressure (BP) in hypertensive patients. However, many would posit that treatment intensification (TI) is not beneficial in the face of suboptimal adherence. We investigated whether the effect of TI on BP varies by adherence. We enrolled 819 patients with hypertension, managed in primary care at an academically-affiliated inner-city hospital. W...
متن کاملChanges in Adherence to Non-Pharmacological Guidelines for Hypertension
This study aimed to compare levels of adherence to non-pharmacological guidelines between patients with and without hypertension diagnoses, and examined temporal changes in adherence during recent decades. We used data from the Korean National Health and Nutrition Examination Survey (1998-2012), including 13,768 Korean hypertensive patients aged ≥ 30 years who were categorized according to the ...
متن کاملPharmacologic Therapy for Pulmonary Arterial Hypertension in Adults
10-74 David Badesch, MD Dr. Badesch has received honoraria for service on steering committees or advisory boards (or as a consultant) to the following companies working in the area of pulmonary hypertension: Actelion/CoTherix, Gilead/Myogen, Encysive, Pfizer, Mondo-Biotech/Mondogen, Biogen IDEC, United Therapeutics/Lung Rx, GlaxoSmithKline, Lilly/ICOS, Bayer, Ikaria, and Arena. He has received ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Canadian Journal of Public Health
سال: 1998
ISSN: 0008-4263,1920-7476
DOI: 10.1007/bf03404493